Navigation Links
New In-Depth Report on Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2019
Date:12/6/2013

Fairfax, VA (PRWEB) December 06, 2013

In their latest Special Report, “The Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2019,” PharmSource experts provide a quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products.

Founded on the industry’s most comprehensive database of the dose CMO industry - PharmSource’s Strategic Advantage Database of Contract Service Providers - the analytical model and assumptions are fully explained so readers can understand how the analysis and conclusions were established. PharmSource is considered to be the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.

Projections are presented for key processing capabilities, including aseptic fill, lyophilized vials and prefilled devices such as syringes, cartridges and proprietary devices. The study analyzes the current capacity and planned additions to capacity of contract manufacturers, as well as the plans by major sponsors to increase in-house capacity.

This 80-page report gives important, expert insight that is not available in any other source. Over 25 tables and more than 20 charts and graphs throughout the report illustrate major points and trends. This report should be required reading for:

  •     CMO executives: this report is an indispensable resource for understanding the industry and a critical input for strategic planning efforts.
  •     Sourcing and procurement executives: this report is a critical resource for understanding crucial components of the supply base that will provide insights for supplier selection and management.
  •     Private equity investors: this report gives a deeper understanding of the market and important insight for identifying potential investment targets.

To learn more about PharmSource's special reports, click here.

About PharmSource
PharmSource Information Services, Inc. is a respected provider of business intelligence on contract drug development and manufacture. PharmSource assists Biotechnology and Pharmaceutical companies in implementing and managing sourcing strategies and programs. They also provide business development products and services to companies that serve the biotechnology and pharmaceutical industries. Since 1996, organizations involved in contract Pharma services have continuously relied on PharmSource publications, databases, surveys and consulting services to provide timely, accurate information and analysis. Visit PharmSource on the web at http://www.pharmsource.com or contact them at +1-703-383-4903 (USA, eastern time-zone).

Read the full story at http://www.prweb.com/releases/2013/12/prweb11396707.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioInformatics LLC Multi-Sponsor Market Report – In-depth Exploration of the U.S. Market for Biosimilar Drugs
2. In-Depth Black Mold Removal Guide Released by My Cleaning Products, Company Offers Complimentary Sample of Molderizer and Safe Shield Along With It
3. The Global Metabolomics Market 2013 Report: An In-Depth Analysis and Forecast of the Market Covering the Leading Competitors in Metabolomics
4. An In-Depth Understanding of the Chinese Pharmaceutical Industry
5. In-depth Research on China Organic Silicon Industry, 2013-2017 (Update Version)
6. In-Depth Research and Development Forecast of China Fluorine Chemical Industry, 2013-2017
7. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
8. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
9. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
10. Interleukin Genetics Reports Third Quarter 2011 Financial Results
11. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots ... scientists from around the world, was today awarded the "Best Science & Technology ... entirely on merit and decided upon by a dedicated team of researchers and ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... spanning the full spectrum of drug and device development, and Prism Clinical ... companies and clinicians, today announced Verified Clinical Trials (VCT) has been ...
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
(Date:1/19/2017)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ), ... a live webcast of its Annual Meeting of Shareholders on Tuesday, ... webcast can be accessed from the BD corporate website at ... 2017. ... BD BD is a global medical technology company that is ...
Breaking Biology Technology:
(Date:1/3/2017)... -- Onitor, provider of digital health technology for consumers, ... biometric data-driven program designed to aid weight loss for ... Consumer Electronics Show (CES) in Las Vegas ... World Health Organization (WHO), have identified lifestyle risks that ... overweight or obese. WHO also states that more people ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
(Date:12/15/2016)... --  WaferGen Bio-systems, Inc. (NASDAQ: WGBS ... that on December 13, 2016, it received a letter ... Market LLC which acknowledged that, as of December 12, ... had been at $1.00 or greater for ten consecutive ... Rule 5550(a)(2) of the Nasdaq Stock Market. ...
Breaking Biology News(10 mins):